发展历程
Built a fully integrated innovative
biopharmaceutical company with capabilities in.
Drug discovery.
Drug development.
Construction of a pilot production facility in Nanjing.
Initiation of Phase III clinical trials for ONC-392.
ONC-782 enters the registration clinical trial phase.
Completed Series B financing.
Developed independently owned intellectual property for innovative products.
The AI-071 project entered the clinical stage.
The ONC-392 project entered Phase II clinical trials.
